Day 1 conference highlights include news from Moderna, BridgeBio

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox.

Hello from sunny San Francisco, where #BiotechVibeWatch2026 has begun. This is Allison DeAngelis, joined here by STAT’s Adam Feuerstein, Matthew Herper, and Elaine Chen.

There’s been endless chatter about the state of biotech lately. And if the cross-country flights from Logan Airport to San Francisco are any indicator, Boston and Kendall Square may still be in trouble. My flight out here was — unusually — not full, and I’ve heard other such examples. Am I scrutinizing the tea leaves too intensely, or is this another sign that Boston biotech is depressed? Email [email protected].

STAT+ Exclusive Story

Already have an account? Log in

Table of Contents

Toggle

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

View All Plans